Come and join us on 6 July and hear 4 AIM CEO’s speak. Brad George, Orosur CEO updates us on Colombia’s Tier-1 gold mine potential, Cliff Gross, CEO at Tekcapital explains how investors benefit from a special dividend. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Share News (AVCT)

Share Price Information for Avacta (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 195.00
Bid: 194.00
Ask: 196.00
Change: 6.00 (3.17%)
Spread: 2.00 (1.03%)
Open: 186.00
High: 197.00
Low: 194.60
Yest. Close: 189.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

Avacta 'delighted' at license agreement with longtime collaborator

(Sharecast News) - Avacta Group agreed a commercial license with New England Biolabs (NEB) to commercialise a science and research assay project using its Affimer technology on Wednesday.

10 Oct 18 16:33

Avacta hails progress on in-house and third-party programmes

(Sharecast News) - Avacta Group posted a slightly wider full-year loss on Wednesday even as it highlighted progress both with its in-house programmes and third parties.

2 Oct 18 15:23

Avacta Annual Revenue Increases But Loss Widens On Higher Expenses

LONDON (Alliance News) - Avacta Group PLC on Tuesday said its loss widened in its recently-ended financial year on higher costs, as it continues to progress Affimer.The reagents developer a

2 Oct 18 09:42

FIL Reduces Avacta Stake To Below 5% Threshold After Deal (ALLISS)

LONDON (Alliance News) - Avacta Group PLC said Thursday that FIL Ltd decreased its stake in the biotechnology company to below 5% after a transaction on Tuesday.FIL lowered its holding to a

23 Aug 18 17:38

Lombard Odier Asset Management Lowers Holding In Avacta (ALLISS)

LONDON (Alliance News) - Avacta Group PLC on Thursday said Lombard Odier Asset Management Europe Ltd reduced its holding in the biotechnology company.In a transaction on Tuesday, Lombard to

23 Aug 18 14:20

UPDATE: Avacta Raises GBP12 Million To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC late Monday said it raised GBP11.6 million before expenses to help fund new drug development partnerships.Early on Monday, to

30 Jul 18 18:17

Avacta Sets GBP11.4 Million Share Offer To Fund New Drug Development (ALLISS)

LONDON (Alliance News) - Biotherapeutics firm Avacta Group PLC on Monday said it plans to raise GBP11.4 million in a share placing and subscription to help fund new drug development is to place at

30 Jul 18 12:48

Avacta enters into 'groundbreaking' drug development partnership

(Sharecast News) - Avacta Group's shares surged after the biotherapeutics developer agreed a co-development partnership with Bach BioSciences, a company commercialising the research of William Bachovchin, professor of developmental, chemical and molecular Biology at Tufts University School of Medicine in Boston.

24 Jul 18 11:26

Avacta Appoints Ex-Immunocore Boss Eliot Forster As Chairman

LONDON (Alliance News) - Biotechnology firm Avacta Group PLC said Monday it appointed ex-Immunocore Ltd boss Eliot Forster as its non-executive chairman.Forster served as Immunocore CEO in

11 Jun 18 10:48

Avacta Says Non-Executive Director Michael Albin To Stand Down Friday

LONDON (Alliance News) - Avacta Group PLC, a healthcare products company that specialises in Affimer products that bind molecules together, said Thursday that non-executive be

29 Mar 18 13:58

DIRECTOR DEALINGS: Avacta Chief Executive Officer Smith Buys Shares

LONDON (Alliance News) - Avacta Group PLC said its Chief Executive Officer Alastair Smith bought shares in the biotechnology company in transaction on Tuesday.Smith at

13 Mar 18 14:26

Avacta expects licensing deal for therapeutics product in 2017, order book swells

(ShareCast News) - Life science firm Avacta expects to have its first licensing deal for Affirmer, its biotherapeutics product, this year as its order book swelled. In an update for the six months ended 31 January, the the company said that its order book for Affimer grew 70% year-on-year, which alo

20 Jan 17 10:17

Avacta Adds Cancer Stem Cell Specialist Evan To Scientific Board

7 Nov 16 09:41

Avacta announces collaboration with Memorial Sloan Kettering Cancer Center

(ShareCast News) - Avacta Group announced a research collaboration with Memorial Sloan Kettering Cancer Center on Wednesday, to evaluate the use of the company's 'Affimer' technology in novel CAR-T cell-based immunotherapy. The AIM-traded firm said CAR-T immunotherapy is a form of cancer treatment i

2 Nov 16 15:59

Avacta Group narrows loss as revenues rise

(ShareCast News) - Biotherapeutic, research and diagnostic reagent developer Avacta Group announced its preliminary results for the year to 31 July on Monday, with revenues and losses in line with market expectations. The AIM-traded company said it was well funded at period end, with cash balances o

17 Oct 16 10:54

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.